Arrows indicate Anaplasma phagocytophilum residing inside host cells. Photo Credit: CDC Public Health Image Library |
Microbe of the Week: Anaplasma phagocytophilum
Welcome to microbe of the week, where we break down the
different disease-causing microbes that lurk inside our tick vectors! This
week’s microbe is Anaplasma phagocytophilum, the causative agent of human
granulocytic anaplasmosis (HGA) or more simply referred to as Anaplasmosis.
What is Anaplasma phagocytophilum?
Anaplasma phagocytophilum (referred to as Anaplasma here on
out) is a tiny, round bacterial species that forms grape-like clusters. It lives
and reproduces inside host immune cells—you know, the cells that are supposed
to protect against foreign invaders. This behavior makes Anaplasma just as
tricky as Borrelia burgdorferi (the bacterial species we covered last week).
Both Anaplasma and Borrelia are transmitted by the black-legged tick (aka deer
tick) in the United States, and other Ixodid ticks around the world. Further,
the reservoir for both bacterial species is the white-footed mouse (Peromyscus
leucopus).
More details on Anaplasma epidemiology and statistics
available on the CDC website at: https://www.cdc.gov/anaplasmosis/stats/index.html
Variants of the Species
Anaplasma phagocytophilum was originally three separate
species under a different genus (Ehrlichia phagocytophila, Ehrlichia equi, and
the agent of human granulocytic ehrlichiosis (HGE)) until reclassification in
2001. Despite this reclassification, infectivity of Anaplasma depends on the
variant of the species. The variant that infects humans (causing HGA) generally
is not the same as the variant that infects animals (a disease known as Tick-borne
Fever or TBF in cattle, sheep, and other ruminants).
Symptoms
Symptoms of Anaplasmosis occur about 1 to 5 days after tick
bite exposure and may be confused with other common illnesses. These symptoms include
fever, chills, severe headache, nausea, vomiting, diarrhea, and loss of
appetite. Serious symptoms are rare but may present if treatment is delayed or
if there are other health issues. Severe late-stage symptoms include
respiratory failure, bleeding problems, organ failure, and sometimes even
death.
See the CDC’s website for more information on symptoms of
Anaplasmosis: https://www.cdc.gov/anaplasmosis/symptoms/index.html
Treatment
The CDC recommends the antibiotic Doxycyline for treating
Anaplasmosis.
Condensed history
- 1932 — Tick-borne fever (TBF) recognized as a distinct tick-borne illness in Scotland.
- 1940 — Anaplasma phagocytophilum animal variant (not yet named such) recognized as causative agent of TBF.
- 1949 — Animal variant of Anaplasma initially coined Rickettsia phagocytophila.
- 1950 to 1989 — TBF recognized in sheep and cattle throughout Europe.
- 1962 — Animal variant of Anaplasma renamed Cytoecetes phagocytophila.
- 1969 — Equine granulocytic ehrlichiosis (now equine granulocytic anaplasmosis (EGA)) found in horses in California.
- 1984 — Animal variant of Anaplasma renamed (again) to Ehrlichia phagocytophila.
- 1994 — First human case of Anaplasmosis recorded, known then as human granulocytic ehrlichiosis.
- 2001 — Increased research reclassifies granulocytic ehrlichiosis diseases to Anaplasma phagocytophilum.
- 2008 — Reported cases of Anaplasmosis experience a steady rise in the US according to the CDC.
- 2017 — 5,762 reported cases to the CDC, a sharp peak from previous years.
- 2018 — CDC reports a reduced case load compared to previous years (4,008). This is the most recent data for cases in the US.
An in-depth breakdown of the history of
Anaplasma was written by Zerai Woldehiwet in 2010 and is available at: https://www-sciencedirect-com.ezp1.lib.umn.edu/science/article/pii/S0304401709005469